Deferoxamine mesylate

別名：Ba 33112, Desferrioxamine B, DFOM, NSC 644468, DFO

製品コード：S5742 純度：99.91%

Deferoxamine mesylate is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent. Deferoxamine is a ferroptosis inhibitor that stabilizes HIF-1α expression and improves HIF-1α transactivity in hypoxic and hyperglycemic states in vitro. Deferoxamine decreases beta-amyloid (Aβ) deposition and induces autophagy.Please do not prepare stock solutions with normal saline or PBS, as precipitation may occur.

CAS No. 138-14-7

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 29500	国内在庫あり
25mg	JPY 22000	国内在庫あり
100mg	JPY 59500	国内在庫あり
1g	JPY 295500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（91）

製品安全説明書

現在のバッチを見る：純度： 99.91%

99.91

Deferoxamine mesylate関連製品

関連製品	Fer-1 (Ferrostatin-1) Erastin RSL3 Liproxstatin-1 FIN56 IKE(Imidazole ketone erastin) UAMC-3203 iFSP1 SRS16-86 SRS11-92	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Highly Selective Inhibitor Library	もっと見る

Ferroptosis阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
HT-29	Cell cycle assay	10 uM	24 hrs	Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 10 uM after 24 hrs	20353152
HT-29	Cell cycle assay	5 uM	24 hrs	Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 5 uM after 24 hrs	20353152
HeLa	Bacteriostatic assay	>100 uM	1 hr	Bacteriostatic activity against Chlamydia trachomatis serovar L2 infected in human HeLa cells assessed as growth inhibition compound treated at >100 uM for 1 hr prior infection measured 24 hrs post infection by microscopy	25027937
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by LDH assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by LDH assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by MTT assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by MTT assay	28285915
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 4.51 μM.	17602603
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 5 μM.	19601577
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 7.35 μM.	19216562
A549	Antiproliferative assay		72 hrs	Antiproliferative activity at human A549 cells after 72 hrs by MTT assay, IC50 = 7.5 μM.	22861499
SK-N-MC	Antiproliferative assay		96 hrs	Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay, IC50 = 8.58 μM.	17064069
SK-N-MC	Cytotoxicity assay		72 hrs	Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 9.89 μM.	20303768
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 10 μM.	22861499
DMS53	Antiproliferative assay		72 hrs	Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay, IC50 = 10 μM.	22861499
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 12.5 μM.	22858101
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 16.81 μM.	28841514
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM.	21055950
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM.	22172311
U2OS	Function assay		30 mins	Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay, EC50 = 17.8 μM.	22172704
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay, IC50 = 21.63 μM.	23312948
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay, IC50 = 22.7 μM.	21846118
SK-N-MC	Cytotoxicity assay		72 hrs	Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 22.7 μM.	23276209
HT29	Cytotoxicity assay		72 hrs	Cytotoxicity against human HT29 cells after 72 hrs by MTS assay, IC50 = 36.1 μM.	18345610
HCT116	Function assay		24 hrs	Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3	24900837
MDCK	Toxicity assay			Toxicity in MDCK cells by MTT method, IC50 = 9.49 μM.	20041672
SK-MN-C	Antiproliferative assay			Antiproliferative activity against human SK-MN-C cells by MTT assay, IC50 = 12.05 μM.	18159922
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50 = 14.22 μM.	17963372
SK-N-MC	Toxicity assay			Toxicity in human SK-N-MC cells by MTT method, IC50 = 16.04 μM.	20041672
HL60	Cytotoxicity assay			Cytotoxicity against human HL60 cells by alamar blue assay, GI50 = 18.4 μM.	23266185
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells, IC50 = 22 μM.	19601577
K562	Cytotoxicity assay			Cytotoxicity against human K562 cells, GI50 = 33.1 μM.	23266185
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Targets

HIF-1α ^[1]

Beta Amyloid ^[1]

Ferroptosis ^[2]

In Vitro
In vitro	Deferoxamine mesylate, the iron chelator and ferroptosis inhibitor, rescues neutrophil death induced by systemic lupus erythematosus (SLE) serum, suggesting that ferroptosis may be the main form of neutrophil death in SLE.^[3]
細胞実験	細胞株	Healthy neutrophil cell
	濃度	1/10/100 μM
	反応時間	16 h
	実験の流れ	Cells are cultured in complete RPMI 1640 basic medium (Gibco) with 100 U/ml penicillin, 100 μg/ml streptomycin and 20% serum from ten randomly selected patients with SLE or age- and sex-matched healthy controls (HCs), and incubated at 37 ℃ in a humidified atmosphere of 20% O₂ and 5% CO₂. HC neutrophil cell viability treated with two ferroptosis inhibitors, LPX-1 (10/100/1,000 nM) or DFO (1/10/100 μM), two necroptosis inhibitors, Nec-1 (10/100/1,000 nM) or NSA (10/100/1,000 nM), or apoptosis inhibitor Z-VAD (0.1/1/10 μM) for 16 h are assessed by flow cytometry.

In Vivo
In Vivo	Deferoxamine mesylate (Ba 33112, Desferrioxamine B, DFOM, NSC 644468) is the mesylate salt of Deferoxamine, which forms iron complexes and is used as a chelating agent.
動物実験	動物モデル	Mongrel dogs
	投与量	25 mg/kg
	投与経路	i.m.

参考
[1] Chuang Guo, et al. Front Aging Neurosci . 2015 Jun 2;7:104. [2] Xue Yao, et al. Neural Regen Res . 2019 Mar;14(3):532-541. [3] Li P, et al. Nat Immunol. 2021 Sep;22(9):1107-1117. [4] Sanan S, et al. Resuscitation. 1989 Feb;17(1):63-75. + 展開

参考

[4] Sanan S, et al. Resuscitation. 1989 Feb;17(1):63-75.

+ 展開

化学情報

分子量	656.79	化学式	C₂₆H₅₂N₆O₁₁S
CAS No.	138-14-7	SDF	--
保管	3 years -20°C powder	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3 years -20°C powder	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	１ケ月-20°Cin solvent

In vitro
Batch:

DMSO : 100 mg/mL ( (152.25 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : 100 mg/mL

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):